Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
platelet-rich plasma + growth factors
- Development stage
- Unknown
- Lead developer
- Ivi Alicante
- Modality
- Cell Therapies, Recombinant Proteins and Enzymes
- Administration
- Intraovarian
01
Overview
Platelet-rich plasma (PRP) supplemented with or acting as a concentrated source of growth factors is an autologous biologic therapy used in regenerative medicine, specifically for the treatment of female infertility. Developed and pioneered by IVI Alicante (part of IVI-RMA Global), the treatment involves the intraovarian injection of a concentrated solution of the patient's own platelets. Upon activation, these platelets release a potent cocktail of growth factors, including Vascular Endothelial Growth Factor (VEGF), Transforming Growth Factor-beta (TGF-β), and Platelet-Derived Growth Factor (PDGF). These factors are hypothesized to stimulate the niche of dormant primordial follicles, promote angiogenesis, and reduce oxidative stress, thereby "rejuvenating" the ovarian environment in patients with diminished ovarian reserve (DOR) or premature ovarian insufficiency (POI). The therapy aims to restore ovarian function and improve the success rates of assisted reproductive technologies.
- Other names
- autologous platelet-rich plasmaPRPovarian PRPPRP-derived growth factorsplatelet-rich plasma
Beyond the preview
Go deeper on platelet-rich plasma + growth factors.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on platelet-rich plasma + growth factors.